<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02044510</url>
  </required_header>
  <id_info>
    <org_study_id>SG193</org_study_id>
    <nct_id>NCT02044510</nct_id>
  </id_info>
  <brief_title>Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients</brief_title>
  <official_title>A Double Blind, Randomized Placebo Controlled Trial Evaluating the Urodynamic and Clinical Efficacy of Mirabegron Among Neurogenic Bladder Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study is a randomized, double blind placebo controlled multicenter study to
      determine the effectiveness of mirabegron in the treatment of neurogenic bladder dysfunction.
      Patients will be randomized into one of two trial arms: mirabegron 25mg for two weeks, with
      escalation to 50mg for the remaining 8 weeks, or matched placebo capsule for two weeks, with
      placebo escalation for the remaining 8 weeks. Each of these trial arms will be stratified
      based on whether the patient is already taking an anticholinergic medication or not. The
      study will treat a total of 144 patients (72 with placebo, 72 with mirabegron). The study
      hypothesis is that mirabegron will result in a statistically superior (increased) urodynamic
      bladder capacity.

      The study duration is 12 weeks, with a 1-4 week run in period where no active or placebo
      treatment will be administered. The primary outcome measure will be based on an increase in
      urodynamic bladder capacity. Secondary outcome measures will be additional urodynamic
      parameters, urinary symptom scales, urinary quality of life indices, and voiding diary
      results.

      Patients who are over 18 years of age with a diagnosis of multiple sclerosis (MS) or spinal
      cord injury (SCI) will be eligible to participate. All eligible patients will have urodynamic
      studies performed within 4 weeks of trial enrollment, and at the end of study (week 9-10).
      Adverse events and study outcomes will be assessed at predefined study time points.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment and small observed effect size
  </why_stopped>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bladder Capacity</measure>
    <time_frame>10 weeks</time_frame>
    <description>Urodynamic bladder capacity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3 Day Voiding Diary</measure>
    <time_frame>10 weeks</time_frame>
    <description>The 3 day voiding diary is a simple patient maintained record of fluid intake, voided volume and incontinence episodes. This will be used to assess number of episodes of urgency incontinence, urinary frequency, longest time between voids, functional capacity, and mean voided volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24hr Urinary Pad Weights</measure>
    <time_frame>10 weeks</time_frame>
    <description>This will determine the amount of urinary incontinence that occurs over a 24hr period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (Bladder Specific)</measure>
    <time_frame>10 weeks</time_frame>
    <description>The Short Form-Qualiveen is a urinary specific quality of life measure developed and studied specifically for neurogenic bladder patients; validity, reliability and responsiveness have been established.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (Incontinence)</measure>
    <time_frame>10 weeks</time_frame>
    <description>The I-QOL is an incontinence specific quality of life tool that has been shown to be a valid, reliable and responsive measurement among patients with neurogenic bladder dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome Measure-NBSS</measure>
    <time_frame>10 weeks</time_frame>
    <description>The Neurogenic bladder symptom score (NBSS) is a symptom specific measure of urinary symptoms developed for patients with neurogenic bladder dysfunction with demonstrated validity and reliability. Minimum score is 0, maximum score is 74. Higher score is worse neurogenic bladder symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Perception of Bladder Condition</measure>
    <time_frame>10 weeks</time_frame>
    <description>The patient perception of bladder condition is a commonly used measure in the assessment of oral medications for the treatment of overactive bladder symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>10 weeks</time_frame>
    <description>Adverse events will be monitored passively. They will be actively monitored for hypertension, tachycardia, and urinary retention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Urodynamic Characteristics: Maximum Detrusor Pressure</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Urodynamic Characteristics: Volume at Maximum Detrusor Pressure</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Urodynamic Characteristics: Bladder Sensation</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Urodynamic Characteristics: Bladder Compliance</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Urodynamic Characteristics: Volume at First Detrusor Overactivity</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Urinary Bladder, Neurogenic</condition>
  <arm_group>
    <arm_group_label>Mirabegron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomised to this arm start with mirabegron 25mg PO daily for two weeks, and then at 2 weeks titrate to 50mg PO daily, and maintain that dose for the duration of the study (8 additional weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inert placebo pill, matching active treatment pill.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirabegron</intervention_name>
    <description>Mirabegron 25mg PO daily for 2 weeks, with dose increase to Mirabegron 50mg PO daily for the remaining 8 weeks.</description>
    <arm_group_label>Mirabegron</arm_group_label>
    <other_name>MYRBETRIQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo capsules to the intervention arm</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Diagnosis of traumatic or nontraumatic suprasacral spinal cord injury (SCI) or
             multiple sclerosis (MS, based on a neurologist assessment and/or the McDonald
             criteria)(28)

          -  Age &gt;18 years

          -  Stable method of bladder management for &gt;3months (either spontaneous or provoked
             voiding, or intermittent catheterization).

          -  Bothersome urinary symptoms (urinary frequency, urgency, or urgency incontinence based
             on standard ICS definitions(29)) and completed 3 day voiding diary demonstrating at
             least 1 episode of non-stress based urinary incontinence over the 72hr period (this
             may be urgency based incontinence or unaware incontinence).

          -  Patient is able to read and speak English

        Exclusion criteria:

        Based on Screening visit history:

          -  Participation in another drug or device study in the 60 days prior to the screening
             visit.

          -  Previous urologic surgery: Transurethral prostatectomy, bladder augmentation,
             sphincterotomy, bladder neck sling, artificial urinary sphincter, catheterizable
             channel, implantable electrostimulator/neuromodulator

          -  Current use of suprapubic catheter/foley catheter

          -  Unstable cardiac disease (uncontrolled hypertension, myocardial infarction, unstable
             angina, severe congestive heart failure (NYHA 3 or 4), ventricular arrhythmia (such as
             torsades de pointes), or stroke within the last 6 months)

          -  Clinically significant abnormal ECG

          -  The investigator believes the patient has an increased risk of QT prolongation (based
             on review of the screening ECG and patients concurrent medications)

          -  History of significant renal dysfunction within 1 year, or serum creatinine &gt;150umol/L
             at screening visit (visit 1).

          -  History of significant liver disease within 1 year, or serum AST/ALT &gt;2 times upper
             limit of normal, GGT &gt;3 times upper limit of normal, total bilirubin &gt;2 times upper
             limit of normal at screening visit (visit 1).

          -  History of pelvic radiation

          -  History of bladder cancer

          -  History of a concurrent malignancy or cancer (except noninvasive skin cancer) within
             the last 5 years. Subjects with a history of cancer are considered eligible if the
             subject has undergone potentially curative therapy and the subject has been considered
             disease free for at least 5 years (with the exception of basal cell or squamous cell
             carcinoma of the skin).

          -  Patient has a history of interstitial cystitis/pelvic pain syndrome

          -  Patient has a history of acute or chronic urinary retention within the last 3 months,
             and is currently not using intermittent catheters

          -  Patient has a history of a tachyarrhythmia

          -  Patient has a history of glaucoma

          -  Patient has a medical condition that may cause noncompliance with the study protocol

          -  In the opinion of the Investigator the patient has a history of significant stress
             urinary incontinence

          -  Patient has signs and symptoms of an active urinary tract infection (symptoms of
             dysuria, foul smelling urine, cloudy urine, increased spasticity, increased autonomic
             dysreflexia, self reported fever, increased incontinence, back/suprapubic pain).

             o Patient will submit urine for culture and sensitivity, undergo treatment, and will
             be eligible for rescreening after treatment.

          -  Female patient who is pregnant or breastfeeding, or plans to become pregnant.

          -  Male patient who is planning on fathering a child during the study or for 28 days
             after the last dose of study drug, or who is planning to donate sperm

          -  Patient refuses to provide written consent

          -  Patient will be unable or unwilling to complete the questionnaires and study visits

          -  In the opinion of the study investigator, it is not in the patient's best interest to
             be enrolled in this study.

        Based on medication and allergy review

          -  The new addition of an anticholinergic medication, or a change to anticholinergic
             dose, within the last 30 days, (bladder specific anticholinergics include oxybutynin,
             tolterodine, fesoterodine, solifenacin, darifenacin, trospium, hyoscine, oxybutynin
             gel or patch, atropine, benzatropine). If previously used and discontinued, these
             medications must have been stopped for &gt;2 weeks

          -  Newly added bladder active medication (or dose change) within the last 2 months
             (Tamsulosin, Silodosin, Terazosin, Baclofen, Diazepam, amitriptyline, Finasteride,
             Dutasteride, DDAVP/desmopressin)

          -  Use of flecainide, propafenone, donepezil, thioridazine, tramadol, aripiprazole,
             desipramine, imipramine, venlafaxine or digoxin

          -  Intravesical onabotulinum toxin use within the last 1 year

          -  Intravesical oxybutynin within the last 3 months

          -  Patient has a previous history of treatment with mirabegron

          -  Patient has a known allergy to mirabegron or a previous adverse reaction to a beta 3
             agonist.

        Based on physical exam

          -  Patient has a postvoid residual &gt; 250mL at study enrollment after repeated tested (1
             attempt to re-void to ensure complete emptying of the bladder) and is not using
             intermittent catheters

          -  Patient has a resting BP &gt;180 mmHg systolic and/or &gt;110 mmHg diastolic after 2 minutes
             of sitting quietly

          -  Patient has a resting heart rate &gt;100bpm after 2 minutes of sitting quietly

          -  In the opinion of the study investigator, it is not in the patient's best interest to
             be enrolled in this study based on a clinically significant abnormality on physical
             exam.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Blayne Welk, MD MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rehabiliation Center, Health Sciences Center</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital and Hotel Dieu Hospital (Queens University)</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western University</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 22, 2014</study_first_submitted>
  <study_first_submitted_qc>January 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2014</study_first_posted>
  <results_first_submitted>June 27, 2018</results_first_submitted>
  <results_first_submitted_qc>June 27, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 7, 2019</results_first_posted>
  <last_update_submitted>January 15, 2019</last_update_submitted>
  <last_update_submitted_qc>January 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Blayne Welk</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Spinal Cord Injuries</keyword>
  <keyword>mirabegron</keyword>
  <keyword>Urodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Neurogenic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 30, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT02044510/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 30, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT02044510/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mirabegron</title>
          <description>Patients randomised to this arm start with mirabegron 25mg PO daily for two weeks, and then at 2 weeks titrate to 50mg PO daily, and maintain that dose for the duration of the study (8 additional weeks).
Mirabegron: Mirabegron 25mg PO daily for 2 weeks, with dose increase to Mirabegron 50mg PO daily for the remaining 8 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Inert placebo pill, matching active treatment pill.
Placebo: Matched placebo capsules to the intervention arm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mirabegron</title>
          <description>Patients randomised to this arm start with mirabegron 25mg PO daily for two weeks, and then at 2 weeks titrate to 50mg PO daily, and maintain that dose for the duration of the study (8 additional weeks).
Mirabegron: Mirabegron 25mg PO daily for 2 weeks, with dose increase to Mirabegron 50mg PO daily for the remaining 8 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Inert placebo pill, matching active treatment pill.
Placebo: Matched placebo capsules to the intervention arm</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" lower_limit="43" upper_limit="58"/>
                    <measurement group_id="B2" value="56" lower_limit="42" upper_limit="65"/>
                    <measurement group_id="B3" value="54" lower_limit="42" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with a Spinal cord injury (SCI), n</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with Mulitple sclerosis (MS), n</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bladder Capacity</title>
        <description>Urodynamic bladder capacity</description>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mirabegron</title>
            <description>Patients randomised to this arm start with mirabegron 25mg PO daily for two weeks, and then at 2 weeks titrate to 50mg PO daily, and maintain that dose for the duration of the study (8 additional weeks).
Mirabegron: Mirabegron 25mg PO daily for 2 weeks, with dose increase to Mirabegron 50mg PO daily for the remaining 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Inert placebo pill, matching active treatment pill.
Placebo: Matched placebo capsules to the intervention arm</description>
          </group>
        </group_list>
        <measure>
          <title>Bladder Capacity</title>
          <description>Urodynamic bladder capacity</description>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="305" lower_limit="234" upper_limit="376"/>
                    <measurement group_id="O2" value="369" lower_limit="298" upper_limit="440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>3 Day Voiding Diary</title>
        <description>The 3 day voiding diary is a simple patient maintained record of fluid intake, voided volume and incontinence episodes. This will be used to assess number of episodes of urgency incontinence, urinary frequency, longest time between voids, functional capacity, and mean voided volume</description>
        <time_frame>10 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>24hr Urinary Pad Weights</title>
        <description>This will determine the amount of urinary incontinence that occurs over a 24hr period.</description>
        <time_frame>10 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life (Bladder Specific)</title>
        <description>The Short Form-Qualiveen is a urinary specific quality of life measure developed and studied specifically for neurogenic bladder patients; validity, reliability and responsiveness have been established.</description>
        <time_frame>10 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life (Incontinence)</title>
        <description>The I-QOL is an incontinence specific quality of life tool that has been shown to be a valid, reliable and responsive measurement among patients with neurogenic bladder dysfunction</description>
        <time_frame>10 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Reported Outcome Measure-NBSS</title>
        <description>The Neurogenic bladder symptom score (NBSS) is a symptom specific measure of urinary symptoms developed for patients with neurogenic bladder dysfunction with demonstrated validity and reliability. Minimum score is 0, maximum score is 74. Higher score is worse neurogenic bladder symptoms.</description>
        <time_frame>10 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Perception of Bladder Condition</title>
        <description>The patient perception of bladder condition is a commonly used measure in the assessment of oral medications for the treatment of overactive bladder symptoms</description>
        <time_frame>10 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Adverse events will be monitored passively. They will be actively monitored for hypertension, tachycardia, and urinary retention.</description>
        <time_frame>10 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Urodynamic Characteristics: Maximum Detrusor Pressure</title>
        <time_frame>10 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Urodynamic Characteristics: Volume at Maximum Detrusor Pressure</title>
        <time_frame>10 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Urodynamic Characteristics: Bladder Sensation</title>
        <time_frame>10 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Urodynamic Characteristics: Bladder Compliance</title>
        <time_frame>10 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Urodynamic Characteristics: Volume at First Detrusor Overactivity</title>
        <time_frame>10 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mirabegron</title>
          <description>Patients randomised to this arm start with mirabegron 25mg PO daily for two weeks, and then at 2 weeks titrate to 50mg PO daily, and maintain that dose for the duration of the study (8 additional weeks).
Mirabegron: Mirabegron 25mg PO daily for 2 weeks, with dose increase to Mirabegron 50mg PO daily for the remaining 8 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Inert placebo pill, matching active treatment pill.
Placebo: Matched placebo capsules to the intervention arm</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mary McKibbon</name_or_title>
      <organization>Lawson Research Institute</organization>
      <phone>5196466367</phone>
      <email>mary.mckibbon@sjhc.london.on.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

